CareDx, Inc. (CDNA) Form 8-K — Jul 30, 2026
$CDNAForm 8-KItems 2.02, 7.01, 9.01Filed Jul 30, 2026, 4:03 PM ET0001217234-26-000045Original filing
CareDx reported second quarter 2026 revenue of $132 million, representing a 52% increase year-over-year driven by a 61% increase in Testing Services revenue. The company reported GAAP net income of $111 million, compared to a net loss of $9 million in the prior year, largely due to a $113 million gain on the sale of its Lab Products business to Eurobio Scientific.
Key figures
- Eps
- 2.15
- Revenue
- 131948000
- Guidance
- $490 million to $500 million
- Net Income
- 110636000
- Revenue Yoy
- 52%
- Cash Position
- 373636000
- Gain On Sale
- 112966000
- Adjusted EBITDA
- 24804000
- Guidance AEBITDA
- $66 million to $78 million
- Testing Services Revenue
- 99927000
Price after filing
1 day: -1.0%7 days: +31.7%30 days: +39.3%
Close on the filing date to close N calendar days later (from $35.75). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.